Publication date: Oct 09, 2024

Treatment modifications adopted during pandemic aimed at reducing infection, myelosuppression, and optimizing hospital resources. This study evaluated outcomes for pediatric patients with ALL who had treatment modifications during pandemic compared to historical cohorts at the National Cancer Institute, Cairo University, Egypt. Bi-directional cohort study included 378 patients. Treatment modifications included omission of specific drugs or adjusting chemotherapy schedules to 6-mercaptopurine/methotrexate. Median follow-up were 45. 1 and 43. 2 months, for cohorts (A) and (B), respectively. The three-year overall survival were 84. 9% and 87. 5% (p = . 48) and three-year relapse free survival were 82. 8% and 86. 5% (p = . 11) for cohorts (A) and (B), respectively. Infection-related mortality was 11% and 4. 4% for cohorts (A) and (B), respectively (p = . 03). Treatment modifications adopted during the pandemic did not adversely affect the outcome of patients with ALL and notably reduced infection-related deaths. Longer follow-up is warranted to validate these findings.

Semantics

Original Article